key: cord-0980654-19zimnoa authors: Koffman, Brian; Mato, Anthony; Byrd, John C.; Danilov, Alexey; Hedrick, Brad; Ujjani, Chaitra; Roeker, Lindsey; Stephens, Deborah M.; Davids, Matthew S.; Pagel, John M.; Shadman, Mazyar title: Management of CLL patients early in the COVID‐19 pandemic: An international survey of CLL experts date: 2020-05-13 journal: Am J Hematol DOI: 10.1002/ajh.25851 sha: 4a7aaad16ad0fb0d0874ba008dc66d1c6759e2df doc_id: 980654 cord_uid: 19zimnoa nan emergency, especially to those with older age or comorbid medical conditions. 1 Patients with chronic lymphocytic leukemia (CLL) have a median age of about 70 years at diagnosis, and the majority suffer from additional medical comorbidities and immunosuppressed state. 2 Therapeutic agents for CLL have immunomodulatory effects that can potentially alter the risk of contracting and the response to infection. 3, 4 The interface of SARS-CoV-2 infection, severity of COVID-19 symptoms, and active treatment of CLL represents a major therapeutic dilemma-should CLL-directed therapy continue or be held? This is particularly true for patients receiving B-cell receptor kinase inhibitors, where abrupt treatment discontinuation can result in rapid decompensation in some patients that could mimic COVID-I9 symptoms. These overlapping syndromes bring forth another layer of complexity to the management of these high-risk CLL patients. Since the beginning of the COVID-19 pandemic, the CLL community has encountered many questions regarding primary prevention strategies, application of diagnostic tests for SARS CoV-2, and optimal management of CLL therapy in patients with COVID-19 illness. In the absence of clinical data guiding management of CLL in the setting of COVID-19, expert opinion is critical until ongoing and planned future studies provide high-quality data for evidence-based guidelines. We administered a survey to a cohort of CLL experts in the The survey was sent to 62 CLL specialists, of whom 59 responded to at least one question, and 44 completed the survey for an overall response rate of 95% and a completion rate of 71%. Most responders were from the US (76%), followed by Europe (19%), Australia (3%), and Canada (2%). Participants were clinicians or clinician/scientists (50% each) and were from academic (90%), non-academic (5%) and Participants were asked about their strategy for testing patients both with the current supply status (ie, limited access to the test) and at a time when the test becomes widely available. We gave experts specific scenarios for common CLL therapies, and asked for their input in patients with or without a history of multiple infections. With the current limited test availability, most experts (62%) considered offering a test to patients who call and report symptoms, while 9.5% only recommended the test for symptomatic patients during a clinic visit. Most experts did not recommend universal testing for all CLL patients in a setting where test supply is limited. No difference in response to these questions based on specific CLL therapeutics and infection history was observed ( Figure S1A ). When experts were asked their advice if testing capacity were unlimited, 23% recommended universal testing for all patients. In comparison, 61% still recommended testing only for patients who call and report symptoms. More experts (38%) were in favor of universal testing for patients with a prior allogeneic stem cell transplant ( Figure S1B) . Table 1 . When asked about a recommendation for IVIG use in patients with CLL and COVID-19, 72% of experts did not recommend IVIG treatment specifically for this viral infection. The CLL specialists uniformly recommended strict social isolation for patients with CLL and emphasized the importance of primary prevention. Experts had a low threshold for testing patients with CLL for SARS-CoV-2. Most favored testing patients with any levels of reported symptoms, even with limited testing availability. With unlimited access, 23% recommended universal testing of CLL patients. While most experts recommended holding CLL-directed therapy in patients with COVID-19, they seem to have a different approach to patients treated with BTKi, with more participants favoring the continuation of ibrutinib and acalabrutinib. The survey did not include questions about the rationale for recommendations, though rationale will be specifically addressed in future surveys planned by the CLL Society. Concerns about disease flare after stopping therapy may, at least in part, explain the higher interest in continuation of BTKis. Also, Expert opinion on the management of CLL therapy in patients positive for SARS-CoV-2 (n = 43) As our understanding of the COVID-19 pandemic changes rapidly, recommendations and practices will evolve. Therefore, the presented data is most relevant to the time of this survey (April 2020). Since the administration of this survey, the American Society of Hematology (ASH) has provided an online resource for frequently asked questions about care of patients with COVID-19 in the setting of hematologic malignancies including CLL. 6 Our survey results generally align with the recommendations by the ASH expert panel. We recognize the inherent selection bias that applies to any survey study, though our high response rate has mitigated non-response bias. While ongoing observational and interventional studies will provide data for future evidence-based guidelines, our survey provides a snapshot of current CLL expert opinion during this rapidly evolving COVID-19 pandemic. Future surveys are planned by the CLL Society to assure an optimal approach to the management of patients with CLL during the COVID-19 pandemic. Covid-19: risk factors for severe disease and death Immune defects in patients with chronic lymphocytic leukemia Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment Ibrutinib treatment improves T cell number and function in CLL patients Btk regulates macrophage polarization in response to lipopolysaccharide COVID-19 and CLL: Frequently Asked Questions ORCID Anthony Mato https://orcid.org/0000-0001-8724-1875Mazyar Shadman https://orcid.org/0000-0002-3365-6562 Additional supporting information may be found online in the Supporting Information section at the end of this article.